---
title: "Regeneron Sinks 10% on Failed Phase 3 Melanoma Trial. What Comes Next for REGN Stock."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286811938.md"
description: "Regeneron Sinks 10% on Failed Phase 3 Melanoma Trial. What Comes Next for REGN Stock."
datetime: "2026-05-18T19:50:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286811938.md)
  - [en](https://longbridge.com/en/news/286811938.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286811938.md)
---

# Regeneron Sinks 10% on Failed Phase 3 Melanoma Trial. What Comes Next for REGN Stock.


### Related Stocks

- [REGN.US](https://longbridge.com/en/quote/REGN.US.md)

## Related News & Research

- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)
- [Regeneron's Phase 3 Melanoma Trial Shows Numeric PFS Benefit But Misses Statistical Significance](https://longbridge.com/en/news/286662524.md)
- [Regeneron’s trial fails to reach statistical significance for primary endpoint](https://longbridge.com/en/news/286848216.md)
- [Regeneron Announces Strategic Collaboration With Parabilis Medicines To Advance Novel Antibody-Helicon Conjugates Across Multiple Therapeutic Areas](https://longbridge.com/en/news/286759146.md)
- [Leerink Partners Reiterates "Market Perform" Rating for Regeneron Pharmaceuticals (NASDAQ:REGN)](https://longbridge.com/en/news/286773280.md)